PT-141

Specifications PT-141

Company: Hilma Biocare
Group: Injection/powder
Active Half-life (min): 120 to 160
Subgroup: Peptide hormone
Dosage: 10 mg
Application (Men): 0,1-1 mg, depending on the treatment plan
Product pack:  1 vial
Content (active): PT-141 (Bremelanotide)
Retains water: No
Aromatization: No

DESCRIPTION

PT-141 is the laboratory code for a drug known as Bremelanotide. It is a peptide, a metabolite of Melanotan-2, lacking the amide C-terminus.

Clinical trials have demonstrated the drug’s effectiveness in the treatment of sexual disorders, including libido and erectile dysfunction. Unlike many selective inhibitors, PT-141 acts not only on the genital blood vessels but also on the central nervous system. It stimulates melanocortin receptors (MC3R, MC4R), increasing libido. The drug can be used by both men and women.

Another clinically proven effect is that the drug promotes tanning by stimulating melanin production by melanocytes.

PROPERTIES

● Stimulation of the central nervous system.
● Activation of the cardiovascular system, leading to increased blood flow to the pelvic organs
● Improved mood and reduced anxiety due to activation of receptors in the medial preoptic area (mPOA) of the brain, which causes the release of dopamine and serotonin.

DOSAGE AND APPLICATION

Injections are administered subcutaneously, or less commonly, intramuscularly. Administration as an intranasal spray is not recommended, as it carries a higher risk of side effects associated with increased blood pressure.

The effect after injection develops within two hours and reaches its peak in the third or fourth hour. The total duration of action reaches 8-10 hours.

The initial effective dose is 0.1-0.3 mg. Depending on the treatment goals and individual tolerability, the dose can be increased to 0.5-1 mg. Dosage can also be calculated based on body weight: 10 mcg of the drug per 1 kg of the patient’s body weight.

Dosages greater than 1.5 mg are not recommended. Dosage more than once a day is also not recommended. The duration of the course and frequency of administration are determined by the attending physician based on the patient’s condition.

CONTRAINDICATIONS

Hypertension, cardiovascular disease, liver disease, kidney disease, cancer, pregnancy and lactation, hypersensitivity to any of the drug’s components. Consult your physician before using the drug.

SIDE EFFECTS

Nausea, flushing, headache, increased blood pressure. In rare cases, local reactions to injections are possible.